Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
- DSP to Seek Additional Indication of Bipolar Depression for Latuda in US
June 11, 2012
- University of Tokyo Hospital to Take Over Development of Takeda’s AD Treatment Candidate
June 11, 2012
- Ethical Drug Sales Up 7.0% in April: Crecon Report
June 11, 2012
- 2012 MR Trend Survey
June 11, 2012
- Shionogi Aims to Boost ARB Product Lineup with Launch of Combination Drugs
June 8, 2012
- Astellas to Collect Additional Data Comparing Tivozanib with Sunitinib
June 8, 2012
- Tuberculosis Treatment Delamanid Demonstrates 53% Increase in SCC: Otsuka
June 8, 2012
- Prescriptions by Generic Names Further Spreading, Amlodipine Most Frequently Prescribed: Pharmacist Survey
June 7, 2012
- Astellas Initiates PIIb Dose Finding Study for AC220 in Europe and US
June 7, 2012
- DSP, Shionogi to Comarket Combination Drug of Irbesartan, Amlodipine
June 7, 2012
- Novartis Pharma Revises Package Insert for Hypertension Treatment Rasilez
June 7, 2012
- Mr Mark Swindell Appointed Head of Specialty Care: Pfizer Japan
June 7, 2012
- Teva Pharma’s Committee Compiles Report on Issues at Former Taiyo Pharmaceutical Factory
June 6, 2012
- Astellas to Collaborate with US Company to Develop Bombesin BB2 Receptor Antagonist
June 6, 2012
- Kyowa Kirin’s UK Subsidiary Acquires Global Commercial Rights to Cancer Pain Drug Except Japan and US
June 6, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…